EQ Equillium, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1746466 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.9%
TTM net income YoY39.5%
TTM EPS YoY39.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-20.1%
Net margin-19.6%
FCF margin-46.5%
EBITDA margin-19.8%
Returns
ROE-38.8%
ROA-21.2%
ROIC (approx.)-3,923.0%
Asset turnover1.08x
Leverage & solvency
Liabilities / assets25.6%
Debt / equity0.00x
Current ratio3.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.36x
Accruals ratio28.8%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $4.39M |
| R&D expense | $2.49M | $2.75M | $2.99M | $1.54M | $1.30M | $4.08M | $5.92M | $7.32M |
| SG&A expense | $2.56M | $2.41M | $2.62M | $2.43M | $3.27M | $2.15M | $2.95M | $1.77M |
| Operating income | -$5.05M | -$5.16M | -$5.61M | -$3.96M | -$4.58M | -$6.23M | -$8.87M | -$4.70M |
| Income tax | — | — | — | $0 | $0 | $0 | $0 | $361,000 |
| Net income | -$4.58M | -$4.69M | -$5.31M | -$3.77M | -$4.23M | -$5.74M | -$8.65M | -$5.79M |
| EBITDA | -$5.02M | -$5.13M | -$5.59M | -$3.94M | -$4.55M | -$6.20M | -$8.84M | -$4.66M |
| EPS (basic) | -0.04 | -0.04 | -0.06 | — | -0.06 | -0.16 | -0.24 | — |
| EPS (diluted) | -0.04 | -0.04 | -0.06 | — | -0.06 | -0.16 | -0.24 | — |
| Weighted avg. shares (diluted) | 111.92M | 111.81M | 96.28M | — | 65.32M | 35.72M | 35.59M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $53.32M | $57.16M | $61.32M | $30.28M | $33.12M | $11.49M | $14.50M | $18.09M |
| Short-term investments | — | — | — | — | $0 | $0 | $0 | $4.49M |
| Receivables | — | — | — | — | — | — | — | $0 |
| Current assets | $54.95M | $57.98M | $62.27M | $31.04M | $33.58M | $11.95M | $16.22M | $24.98M |
| PP&E, net | $164,000 | $188,000 | $214,000 | $164,000 | $174,000 | $201,000 | $233,000 | $262,000 |
| Total assets | $55.81M | $58.67M | $63.08M | $31.89M | $34.51M | $12.40M | $16.73M | $25.60M |
| Current liabilities | $2.82M | $2.48M | $3.35M | $2.93M | $3.09M | $7.23M | $6.00M | $6.36M |
| Total liabilities | $3.13M | $2.65M | $3.60M | $3.29M | $3.57M | $7.34M | $6.15M | $6.54M |
| Shareholders' equity | $52.68M | $56.02M | $59.49M | $28.60M | $30.94M | $5.06M | $10.58M | $19.06M |
| Shares outstanding | 63.41M | 63.41M | 63.23M | 61.46M | 60.68M | 35.72M | 35.72M | 35.56M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.83M | -$4.11M | -$4.30M | -$3.13M | -$8.43M | -$3.01M | -$8.17M | -$3.30M |
| Capital expenditure | $0 | $71,000 | $3,000 | $44,000 | $0 | $0 | $4,000 | $4,000 |
| Free cash flow | -$3.83M | -$4.18M | -$4.30M | -$3.18M | -$8.43M | -$3.01M | -$8.17M | -$3.30M |
| Investing cash flow | $0 | -$71,000 | -$3,000 | -$32,000 | $0 | $0 | $4.50M | $6.00M |
| Financing cash flow | -$1,000 | $42,000 | $35.35M | $283,000 | $30.07M | -$16,000 | $91,000 | $73,000 |
| Depreciation & amortization | $24,000 | $26,000 | $24,000 | $23,000 | $28,000 | $32,000 | $33,000 | $35,000 |
| Stock-based compensation | $1.26M | $1.09M | $930,000 | $737,000 | $401,000 | $563,000 | $621,000 | $821,000 |
Free plan shows the latest 8 periods; Pro shows all 38 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.